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KEY POINTS
 The initial therapy for all of the autoinflammatory syndromes is the control of fever, pain, or the
symptoms derived from the inflammatory reaction.
 The initial effort should focus on making the precise diagnosis. This strategy facilitates the choice of
appropriate initial therapy, which has been defined for many of these syndromes and diseases.
 Accurate diagnosis is often difficult; rendering symptommanagement the mainstay of initial therapy
while the definitive diagnosis remains elusive.
 Steroids are not considered useful in the autoinflammatory syndromes, yet they still play an impor-
tant role in the early treatment of these diseases.
 Colchicine has been approved for the treatment of familial Mediterranean fever and its late
complications.
 Antitumor necrosis factor therapy has been used and proved useful in several autoinflammatory
diseases.
 The most recent acquisition for the treatment of autoinflammatory syndromes is anti-interleukin 1,
anakinra, rilonacept, and canakinumab, with good results in many of the autoinflammatory
syndromes.
 New molecules and pathways of disease will facilitate the development of effective therapies.INTRODUCTION
The autoinflammatory disorders are an expanding
group of diseases characterized by recurrent sys-
temic inflammation in the absence of infection,
autoantibodies, or antigen-specific T cells; they
are thus probably related to a primary dysfunction
of the innate immune system, with no adaptive
immune deregulation. Dysfunction of the innate
immune system includes abnormal responses
to pathogens associated with the lipopolysaccha-
ride and peptidoglycan of myeloid cells, such as
neutrophils and monocytes in blood and tissues,Neither of the authors has any financial conflicts.
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cytokines and their receptors, like interleukin 1b
(IL-1b), tumor necrosis factor a (TNF-a), and
others1; thus, these substances and molecules
have become the targets for present and future
therapies.
The autoinflammatory diseases include heredi-
tary disorders like: familial Mediterranean fever
(FMF), mevalonate kinase (MK) deficiency, tumor
necrosis factor receptor–associated periodic syn-
drome (TRAPS), cryopyrin-associated periodic
syndrome (CAPS), familial cold autoinflammatory
syndrome (FCAS), Muckle-Wells syndromeSuite H, Coral Gables, FL 33146, USA; b Children’s
NY 10467, USA
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Sterba & Sterba508(MWS), chronic infantile neurologic, cutaneous,
and articular (CINCA) syndrome, Blau syndrome,
hyperimmunoglobulin D syndrome (HIDS), pyo-
genic sterile arthritis, pyoderma gangrenosum
and acne (PAPA) syndrome, chronic recurrent
multifocal osteomyelitis; some multifactorial disor-
ders like Crohn and Behc¸et disease, juvenile idio-
pathic arthritis (JIA), adult Still disease, and
macrophage activation syndrome (MAS) are
considered autoinflammatory diseases; so are pe-
riodic fever, aphthous stomatitis, and adenopathy
(PFAPA) syndrome and Majeed syndrome.
TREATMENT
The initial therapy for all the autoinflammatory syn-
dromes is the control of fever, pain, or the symp-
toms derived from the inflammatory reaction.
Antiinflammatory medications are the initial choice;
nonsteroidal antiinflammatory drugs (NSAIDs) have
been used with variable success for decades; so
have systemic steroids.
The initial effort should focus on making the pre-
cise diagnosis. This goal facilitates the choice of
appropriate initial therapy, which has been defined
for many of these syndromes and diseases. Accu-
rate diagnosis is often difficult, rendering symptom
management the mainstay of initial therapy while
the definitive diagnosis remains elusive.
Chronic management includes symptom man-
agement and prevention of complications of long-
term disease and treatment, including amyloidosis
and premature coronary artery disease (Table 1).
Nonspecific Medications
The initial drug management includes corticoste-
roids or nonsteroidal medications, as well as
others with antiinflammatory effects, as follows.
Cimetidine
Cimetidine is a histamine 2 (H2) receptor antago-
nist that inhibits stomach acid production. Used
to treat and reduce the symptoms of gastritis
and peptic ulcer disease, it has been shown de-
batably useful in the treatment of herpes simplexTable 1
Overall summary of hereditary periodic fever syndro
Feature FMF HIDS
Treatment Colchicine to prevent
attacks and for
long-term prevention
of amyloidosis
Supportive
NSAIDs,
prednisone,
simvastatin
Abbreviations: FCU, familial cold urticaria; HIDS, hyperimmun1 and 2, herpes zoster virus, common warts,
some inflammatory conditions associated with
calcifications, and so forth. It has also been used
to modify epidermal growth factor, vascular endo-
thelial growth factor, and E-selectin, for the treat-
ment of several cancers and their metastasis.
Cimetidine was shown to be of some benefit
in the pain of interstitial cystitis. Cimetidine has
been used in PFAPA syndrome, with resolution
of the fever and some of the other manifestations
of the syndrome; at a dose of 20 mg/kg/d, cimeti-
dine has a response greater than 50%; the mech-
anism of action is not known, but has been linked
to inhibition of T-suppressor cells by blocking
H2-receptors, with minimal side effects.
2,3
Statins
The involvement of MK in the cholesterol synthesis
pathway encouraged the introduction of statins in
the management of MK deficiency and HIDS;
good results were obtained in a small group of
patients.4 MK plays an essential role in the choles-
terol synthesis pathway; during cholesterol biosyn-
thesis, 3-hydroxy-3-methylglutaryl-coenzyme A
(HMG-CoA) reductase (the enzyme inhibited by
statins) converts HMG-CoA to mevalonate. This
conversion is blocked when a mutation in the
MVK gene exists and mevalonate is not converted
to mevalonate phosphate, causing an increase in
mevalonic acid in serum, tissues, and urine. The
absence of a negative feedback loop, naturally
provided by the presence of the end products of
synthesis, leads to increased HMG-CoA reductase
activity, consequently increasing serum, tissue,
and urine levels of mevalonic acid. The inhibition
of MK also activates caspase 1 and decreases iso-
prenoids, which increase IL-1b. The blockade of
these mediators may soon help to clarify the path-
ophysiology of these diseases.
NSAIDs
NSAIDs are nonselective inhibitors of cyclooxyge-
nase, acting on both isoenzymes Cox1 and Cox2,
causing a reversible inhibition, which is in contrastmes
TRAPS MWS FCU CINCA
NSAIDs and
steroids,
anti-TNF,
anti-IL-1
NSAIDs and
steroids,
anti-IL1
Anti-IL-1 Anti-IL-1
oglobulinemia D with periodic fever syndrome.
Controlling Inflammation 509with that produced by aspirin, which is irreversible,
with no formation of prostaglandins and throm-
boxane (mediators of inflammation). In crystal-
induced arthritis, NSAIDs have been shown to
inhibit urate crystal phagocytosis. The mechanism
of action of NSAIDs is to block the formation of
prostaglandin E2, which regulates neurons within
the hypothalamus responsible for the generation
of temperature increase or fever.5
NSAIDS are used initially in the antiinflammatory
syndromes to relieve constitutional symptoms or
inflammatory signs like fever and arthritis, but in
most instances, they are not the mainstay of ther-
apy. Nonsteroidal and steroidal drugs have been
used in Majeed syndrome for the control of symp-
toms, but the long-term management of the he-
matologic manifestations is accomplished by
splenectomy and transfusions.6
Corticosteroids
Prednisone is a glucocorticoid converted in the
liver to prednisolone, its active form. Isolated in
1950 and introduced for usage in 1955, it has
been the mainstay of therapy for many autoim-
mune and inflammatory diseases in which steroids
are helpful. Steroids are not considered useful in
the autoinflammatory syndromes, yet they still
play an important role in their early treatment.
Steroids are the main treatment option in acute
attacks of HIDS. Patients with PFAPA syndrome
are treated with prednisone for their fever. In
some situations, PAPA syndrome responds well
to oral glucocorticoids. Steroids are used in the
febrile crisis of TRAPS, but their use in the chronic
setting is best avoided. Low-dose steroids are rec-
ommended in JIA and in adult Still disease; pred-
nisone 1 to 5 mg per day is used, although some
patients may require 1 to 2 mg/kg/d, usually in
divided doses.
In MAS, the usual starting dosage is pulse meth-
ylprednisolone at 30 mg/kg/d for 3 to 5 days or
prednisone 1 to 2 mg/kg/d, usually in divided
doses, 2 or 3 times a day.7
Colchicine
Historically, colchicine has been used for nearly
all the rheumatic diseases. It was described for
the treatment of rheumatism and swelling in the
Egyptian Ebers Papyrus (ca 1500 BC). Extracted
from the meadow saffron (Colchicum autumnale)
in the early 1970s, colchicine was found useful in
the acute management of FMF,8 as well as in the
prevention of its long-term complications like
amyloidosis.9 Colchicine was only approved by
the US Food and Drug Administration (FDA) in
August, 2009 for use in gout and FMF. Themechanism of action of colchicine is believed to
be inhibition of microtubule polymerization by
tubulin binding, which blocks cell mitosis in neu-
trophils, and by antiinflammatory mechanisms
involving altered expression of adhesion mole-
cules and chemotactic factors, coming from the
generation of reactive oxygen species occurring
in crystal-induced arthritis.
Amyloidosis is a feared long-term complication
of FMF; it results from accumulation of serum
amyloid A (SAA) protein, deposited mainly in the
kidney. A major manifestation of amyloidosis is
renal injury, whichmay lead to proteinuria renal fail-
ure. Patients are normotensive, with no hematuria.
Since the adoption of colchicine for FMF, the prev-
alence of amyloidosis among patients with FMF
has decreased significantly. For adults, the dose
of colchicine is 0.5 to 1mg/d; for children, the start-
ing dose should be 0.5 mg/d or less if younger than
5 years, 1 mg/d for children 5 to 10 years, and
1.5 mg/d for those older than 10 years; dosage
can be increased in a stepwise fashion up to a
maximumof 2mg/d. A few patients do not respond
to colchicine, usually because of poor treatment
adherence; at the suggested dosage, it is a safe
drug; side effects, including gastrointestinal, he-
matologic, and neuromuscular symptoms, are
rare.
Bisphosphonates
These medications are being used and positive
outcomes obtained with pamidronate and zolen-
dronic acid in the treatment of SAPHO (synovitis,
acne, palmoplantar pustulosis, hyperostosis, and
osteitis) syndrome,10,11 via their antiosteoclastic
effect and supposed antiinflammatory action,
may be related to the suppression of TNF-a.
Immunosuppressive Drugs
Methotrexate and cyclosporine have been tried in
autoinflammatory disorders but proved ineffective
in many, both as disease modifiers and steroid-
sparing drugs. In TRAPS, they do not reduce the
frequency or intensity of flares and have no effect
in secondary amyloidosis.12,13 In Blau syndrome,
they have been used with limited success. Cyclo-
sporine has been used in the treatment of MAS in
association with steroids and is used for disease
control, with good results7; anakinra in MAS has
been shown to be effective.
TNF Inhibitors
In 1999, the cloning of the gene for the TNF re-
ceptor defined the cause of TRAPS.11 Etanercept,
a soluble antagonist of TNF, has proved useful in
patients with TRAPS.14 Worsening of disease has
Sterba & Sterba510been seen in some patients treated with anti-
TNF15; this phenomenon resembles the contra-
dictory responses observed in some patients
with JIA treated with anti-TNF medication who
go on to develop MAS, when the MAS is induced
or favored by the use of the anti-TNF medication,
suggesting that it should be used with caution.16
Infliximab, another TNF molecule and receptor
antagonist, has been used in TRAPS and in Blau
syndrome, with good responses, and in some
cases, with reduced long-term complications;
the response of amyloid deposition is controver-
sial, and there is no definitive information on the
effectiveness of anti-TNF in reducing long-term
complications.
Anti-TNF medication has been described as
useful in case reports for SAPHO syndrome.17
Anti-IL-1
Short-acting
Anakinra, a receptor antagonist for IL-1, showed
no efficacy in sepsis and rheumatoid arthritis. IL-1
inhibition also occurs in systemic idiopathic
arthritis and recurrent pericarditis of noninfectious
origin. Anakinra has been used in systemic-onset
JIA, with excellent results, and it has been used
to prevent attacks and reduce systemic inflamma-
tory markers in patients with colchicine-resistant
FMF, HIDS, and even etanercept-resistant TRAPS.
Similarly, remarkable responses were also re-
ported in patients with Blau syndrome, PAPA syn-
drome, and deficiency of IL-1-receptor antagonist.
Anakinra is effective during episodes of acute
gout.18
Anakinra has been shown to prevent cold-
induced symptoms when administered to patients
with FCAS before a cold room challenge.19
Excessive production of IL-1 is seen in dis-
eases like MWS, CINCA syndrome, and neonatal
onset multisystem inflammatory disease (NOMID),
and excellent therapeutic responses have been
described.20
The dosage used of anakinra varies from 0.3 to
3 mg/kg/d, in divided doses.
Long-acting
Rilonacept is a recombinant fusion protein with a
half-life of 8.6 days, it has a high affinity for IL-1b
and also for IL-1a and IL-1 receptor accessory pro-
tein; it is usedweekly at a dose of, for patients aged
12 years or older, 4.4 mg/kg, up to a maximum of
320 mg, delivered as 1 or 2 subcutaneous injec-
tions with a maximum single-injection volume of
2mL. If the initial dose is of 2 injections, they should
be given on the same day at 2 different sites;
dosing should be continued with a once-weekly in-
jection of 2.2 mg/kg, up to a maximum of 160 mg,administered as a single subcutaneous injection of
up to 2 mL. Canakinumab is a humanized mono-
clonal antibody against IL-b; its half-life is
28 days and it may be dosed every 8 weeks; for
body weights greater than 40 kg, the recommen-
ded dose is 150 mg as a single dose via subcu-
taneous injection; for body weights between
15 kg and 40 kg, the recommended dose is
2 mg/kg as single subcutaneous injections; for
children 15 to 40 kg with inadequate response,
the dose can be increased to 3 mg/kg as single
subcutaneous injections.
Both rinolacept and canakinumab are useful in
the treatment of NOMID, FCAS, MWS, HIDS,
and, as recently reported,21 JIA and in CAPS,
both are FDA approved for this use.22,23 Also, in
crystal-induced arthritis, canakinumab was used
with good results.24 Recently, results of the treat-
ment of Blau syndrome with canakinumab showed
good responses.25 Two randomized trials with
canakinumab in JIA reported benefits.26 Also, tozi-
lizumab an anti-IL-6, used in JIA, was recently
described as effective.27Adverse Effects of Biological Therapies
Experiences with autoimmune disease have
shown increases in the rates of mild to severe
bacterial and viral infections, but the pathophysi-
ology of these diseases is different and it is diffi-
cult to extrapolate. Nevertheless, at least a good
history to exclude for tuberculosis, fungi, and viral
diseases such as hepatitis C and B is mandatory;
on the other hand, the use of immune-suppressive
therapies might increase the risk of opportunistic
infections in patients with autoimmune dis-
eases.28 The situation is different for the autoin-
flammatory syndromes. Increased rates of
meningitis and urosepsis have been described in
small CAPS trials with both rilonacept and canaki-
numab. Injection-site reactions are common with
all antileukins.SUMMARY
The continuous advance in the search for the
cause and pathogenesis of the autoinflammatory
syndromes, as well as reports of the efficacy
of specific inflammation-mediator suppressors,
has changed the way these syndromes are
approached and treated; both the acute and
long-term treatment of these diseases has
improved significantly. Etiologic and pathophysio-
logic manipulation is and will be the future for con-
trolling, even curing, this new and rare set of
diseases.
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